GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » Cash per Share

CEL-SCI (CEL-SCI) Cash per Share : $0.07 (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is CEL-SCI Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). CEL-SCI's Cash per Share for the quarter that ended in Dec. 2023 was $0.07.


CEL-SCI Cash per Share Historical Data

The historical data trend for CEL-SCI's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI Cash per Share Chart

CEL-SCI Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.40 0.98 0.52 0.09

CEL-SCI Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.23 0.12 0.09 0.07

CEL-SCI Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

CEL-SCI's Cash per Share for the fiscal year that ended in Sep. 2023 is calculated as:

CEL-SCI's Cash per Share for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CEL-SCI  (AMEX:CVM) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.


CEL-SCI Cash per Share Related Terms

Thank you for viewing the detailed overview of CEL-SCI's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


CEL-SCI (CEL-SCI) Business Description

Traded in Other Exchanges
Address
8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Executives
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Peter R Young director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
John Cipriano officer: Senior Vice President 8229 BOONE BLVD, SUITE 802, VIENNA VA 22182
Robert Eugene Watson director 245 N. HIGHLAND AVE NE, SUITE 230-296, ATLANTA GA 30307
Bruno Jean-marie Baillavoine director 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Eyal Talor officer: Chief Scientific Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Geert R Kersten director, officer: Chief Executive Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Daniel H Zimmerman officer: Sr. Vice President, Research 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Patricia B Prichep officer: Sr. Vice President, Operations 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Clara Maximilian De director, officer: President
C Richard Kinsolving director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Alexander G Esterhazy director 8229 BOONE BLVD, STE 802, VIENNA VA 22182